Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases

Pharmacology and Therapeutics

Volumn 100, Issue 2, 2003, Pages 119-139

  Van Rompay, An R ^a   Johansson, Magnus ^b   Karlsson, Anna ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticancer therapy; Antiviral therapy; Chemotherapy; Deoxyribonucleoside kinase; Nucleoside analogue; Ribonucleoside kinase

Indexed keywords

ABT 702; AMPRENAVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CLADRIBINE; COMPLEMENTARY DNA; CYTARABINE; DELAVIRDINE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; DEOXYRIBONUCLEOTIDE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; FLUDARABINE; GEMCITABINE; GP 515; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBONUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE KINASE 1; THYMIDINE KINASE 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CANCER; CANCER CHEMOTHERAPY; CATALYSIS; CELL CYCLE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHROMOSOMAL LOCALIZATION; DELAYED CYTOTOXICITY; DNA PURIFICATION; DNA REPLICATION; DNA SYNTHESIS; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME LOCALIZATION; GENE LOCATION; GENE SEQUENCE; HUMAN; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION; VIRUS INFECTION;

EID: 0242552804     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2003.07.001     Document Type: Review

References (229)

1. Absil J., Tuilie M., Roux J.M. Electrophoretically distinct forms of uridine kinase in rat. Tissue distribution and age-dependence. Biochem J. 185:1980;273-276.
2. Agarwal R.P., Olivero O.A. Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3′-azido-2′,3′- dideoxythymidine. Mutat Res. 390:1997;223-231.
3. Aguayo A., Cortes J.E., Kantarjian H.M., Beran M., Gandhi V., Plunkett W., Kurtzberg J., Keating M.J. Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T cell blastic phase: a case report and review of the literature. Cancer. 85:1999;58-64.
4. Ahluwalia G.S., Gao W.Y., Mitsuya H., Johns D.G. 2′,3′- Didehydro-3′-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Mol Pharmacol. 50:1996;160-165.
5. Ahmed N.K., Baker D.R. Properties of uridine-cytidine kinase derived from L1210 leukemia cells. Cancer Res. 40:1980;3559-3563.
6. Ahmed N.K., Welch A.D. Some properties of uridine-cytidine kinase from a human malignant lymphoma. Cancer Res. 39:1979;3102-3106.
7. Anderson E.P. Nucleoside and nucleotide kinases (Review). 3rd ed. Boyer P.D. The Enzymes. vol. 9:1973;49-96 Academic Press, New York.
8. Anderson K.S. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase. Biochim Biophys Acta. 1587:2002;296-299.
9. Anderson E.P., Brockman R.W. Feedback inhibition of uridine kinase by cytidine triphosphate and uridine triphosphate. Biochim Biophys Acta. 91:1964;380-386.
10. Andres C.M., Fox I.H. Purification and properties of human placenta adenosine kinase. J Biol Chem. 254:1979;11388-11393.
11. Arnér E.S.J., Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 67:1995;155-186.
12. Arnér E.S.J., Spasokoukotskaja T., Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun. 188:1992;712-718.
13. Arpaia E., Benveniste P., Di Cristofano A., Gu Y., Dalal I., Kelly S., Hershfield M., Pandolfi P.P., Roifman C.M., Cohen A. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med. 191:2000;2197-2208.
14. August E.M., Birks E.M., Prusoff W.H. 3′-Deoxythymidin-2′- ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol Pharmacol. 39:1991;246-249.
15. Baldwin S.A., Mackey J.R., Cass C.E., Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development (Review). Mol Med Today. 5:1999;216-224.
16. Balzarini J., Herdewijn P., De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′, 3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem. 264:1989;6127-6133.
17. Balzarini J., Zhu C., De Clercq E., Péréz- Péréz M.J., Chamorro C., Camarasa M.J., Karlsson A. Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase 2. Biochem J. 351:2000;161-171.
18. Balzarini J., Degreve B., Zhu C., Durini E., Porcu L., De Clercq E., Karlsson A., Manfredini S. 2′-O-acyl/alkyl-substituted arabinosyl nucleosides as inhibitors of human mitochondrial thymidine kinase. Biochem Pharmacol. 61:2001;727-732.
19. Balzarini J., Hernandez A.I., Roche P., Esnouf R., Karlsson A., Camarasa M.J., Perez-Perez M.J. Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase. Mol Pharmacol. 63:2003;263-270.
20. Barile M., Valenti D., Quagliariello E., Passarella S. Mitochondria as cell targets of AZT (zidovudine). Gen Pharmacol. 31:1998;531-538.
21. Berne R.M. Adenosine: a cardioprotective and therapeutic agent. Cardiovasc Res. 27:1993;2.
22. Beutler E., Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 93:1996;1716-1720.
23. Bohman C., Eriksson S. Mammalian deoxynucleoside kinases. Biochem Life Sci Adv. 9:1990;11-35.
24. Bradshaw H.D. Jr. Human thymidine kinase gene: molecular cloning and nucleotide sequence of a cDNA expressible in mammalian cells. Mol Cell Biol. 4:1984;2316-2320.
25. Burton T.R., Kashour T., Wright J.A., Amara F.M. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). Int J Oncol. 22:2003;21-31.
26. Canellakis E.S. Pyrimidine metabolism: II. Enzymatic pathway of uracil anabolism. J Biol Chem. 227:1957;329-338.
27. Capizzi R.L., Yang J.L., Cheng E., Bjornsson T., Sahasrabudhe D., Tan R.S., Cheng Y.C. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol. 12:1983;763-771.
28. Carson D.A., Kaye J., Seegmiller J.E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci USA. 74:1977;5677-5681.
29. Carson D.A., Wasson D.B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 62:1983;737-743.
30. Cass C.E., Young J.D., Baldwin S.A., Cabrita M.A., Graham K.A., Griffiths M., Jennings L.L., Mackey J.R., Ng A.M., Ritzel M.W., Vickers M.F., Yao S.Y. Nucleoside transporters of mammalian cells (Review). Pharm Biotechnol. 12:1999;313-352.
31. Chandra J., Månsson E., Gogvadze V., Kaufmann S.H., Albertioni F., Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood. 99:2002;655-663.
32. Chang C.N., Doong S.L., Zhou J.H., Beach J.W., Jeong L.S., Chu C.K., Tsai C.H., Cheng Y.C., Liotta D., Schinazi R. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy- 3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem. 267:1992;13938-13942.
33. Chang C.N., Skalski V., Zhou J.H., Cheng Y.C. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 267:1992;22414-22420.
34. Chariot P., Drogou I., de Lacroix-Szmania I., Eliezer-Vanerot M.C., Chazaud B., Lombes A., Schaeffer A., Zafrani E.S. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 30:1999;156-160.
35. Chen C.H., Vazquez-Padua M., Cheng Y.C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 39:1991;625-628.
36. Cheng N., Payne R.C., Traut T.W. Regulation of uridine kinase. Evidence for a regulatory site. J Biol Chem. 261:1986;13006-13012.
37. Chottiner E.G., Shewach D.S., Datta N.S., Ashcraft E., Gribbin D., Ginsburg D., Fox I.H., Mitchell B.S. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA. 88:1991;1531-1535.
38. Cihak A., Broucek J. Dual effect of 5-azacytidine on the synthesis of liver RNA. Lack of the relationship between metabolic transformation of orotic acid in vitro and its incorporation in vivo. Biochem Pharmacol. 21:1972;2497-2507.
39. Cihak A., Rada B. Uridine kinase: properties, biological significance and chemotherapeutic aspects (a review). Neoplasma. 23:1976;233-257.
40. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 361(9374):2003;2045-2046.
41. Coates J.A.V., Cammack N., Jenkinson H.J., Mutton I.M., Pearson B.A., Storer R., Cameron J.M., Penn C.R. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 36:1992;202-205.
42. Consoli U., El-Tounsi I., Sandoval A., Snell V., Kleine H.D., Brown W., Robinson J.R., DiRaimondo F., Plunkett W., Andreeff M. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood. 91:1998;1742-1748.
43. Cook W.J., Delucas L.J., Chattopadhyay D. Crystal structure of adenosine kinase from Toxoplasma gondii at 1.8 Å resolution. Protein Sci. 9:2000;704-712.
44. Cooney D.A., Dalal M., Mitsuya H., McMahon J.B., Nadkarni M., Balzarini J., Broder S., Johns D.G. Initial studies on the cellular pharmacology of 2′,3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 35:1986;265-268.
45. Cronstein B.N. Molecular mechanism of methotrexate action in inflammation. Inflammation. 16:1992;411-423.
46. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 6:2000;1375-1379.
47. Curbo, C. (2001). Nucleoside analog phosphorylation in the mitochondria: studies on molecular targets of the anti-leukemic compound 9-β-D- arabinofuranosylguanine. MSc Thesis. Stockholm: Karolinska Institute.
48. Curbo S., Zhu C., Johansson M., Balzarini J., Karlsson A. Dual mechanisms of 9-β-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells. Biochem Biophys Res Commun. 285:2001;40-45.
49. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst. 6:2001;14-20.
50. De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys Acta. 1587:2002;258-275.
51. Dubinina I.G., Shkurko V.G., Vornovitskaya G.I. Isolation and properties of uridine kinase from Zajdela ascites hepatoma cells. Biokhimi. 46:1982;1503-1511.
52. Dumontet C., Fabianowska-Majewska K., Mantincic D., Callet Bauchu E., Tigaud I., Gandhi V., Lepoivre M., Peters G.J., Rolland M.O., Wyczechowska D., Fang X., Gazzo S., Voorn D.A., Vanier-Viornery A., MacKey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 106:1999;78-85.
53. Durham J.P., Ives D.H. Intracellular distribution of pyrimidine nucleoside phosphorylating activities in rat thymus. Exp Cell Res. 70:1972;97-105.
54. Ellims P.H., Van der Weyden M.B. Kinetic mechanism and inhibition of human liver thymidine kinase. Biochim Biophys Acta. 660:1981;238-242.
55. Eriksson S., Wang L. Substrate specificities, expression and primary sequences of deoxynucleoside kinases; implication for chemotherapy. Nucleosides Nucleotides. 16:1997;653-659.
56. Firestein G.S., Boyle D., Bullough D.A., Gruber H.E., Sajjadi F.G., Montag A., Sambol B., Mullane K.M. Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol. 152:1994;5853-5859.
57. Fleischmann J., Kremmer E., Greenspan J.S., Grässer F.A., Niedobitek G. Expression of viral and human dUTPase in Epstein-Barr virus associated diseases. J Med Virol. 68:2002;568-573.
58. Fox I.H., Kelley W.N. The role of adenosine and 2′-deoxyadenosine in mammalian cells. Annu Rev Biochem. 47:1978;655-686.
59. Francke U., Thompson L. Regional mapping, by exclusion of adenosine kinase (ADK) on human chromosome 10 using the gene dosage approach. Cytogenet Cell Genet. 25:1979;156.
60. Fulchignoni-Lataud M.-C., Roux J.-M. Uridine kinase molecular species and uridine uptake in some variants of rat hepatomas. J Cell Physiol. 118:1984;34-38.
61. Fulchignoni-Lataud M.-C., Tuilie M., Roux J.-M. Uridine-cytidine kinase from foetal and adult rat liver: purification and study of some properties. Eur J Biochem. 69:1976;217-222.
62. Furman P.A., Fyfe J.A., St Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 83:1986;8333-8337.
63. Furman P.A., Davis M., Liotta D.C., Paff M., Frick L.W., Nelson D.J., Dornsife R.E., Wurster J.A., Wilson L.J., Fyfe J.A., Tuttle J.V., Miller W.H., Condreay L., Averett D.R., Schinazi R.F., Painter G.R. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 36:1992;2686-2692.
64. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanism of drug resistance and reversal strategies. Leukemia. 15:2001;875-890.
65. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3:2002;415-424.
66. Genini D., Adachi S., Chao Q., Rose D.W., Carrera C.J., Cottam H.B., Carson D.A., Leoni L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 96:2000;3537-3543.
67. Gentry G.A. Viral thymidine kinases and their relatives. Pharmacol Ther. 54:1992;319-355.
68. Girard P.M., Pegram P.S., Diquet B., Anderson R., Raffi F., Tubiana R., Sereni D., Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr. 23:2000;227-235.
69. Gower W.R. Jr., Carr M.C., Ives D.H. Deoxyguanosine kinase. Distinct molecular forms in mitochondria and cytosol. J Biol Chem. 254:1979;2180-2183.
70. Gray N.M., Marr C.L., Penn C.R., Cameron J.M., Bethell R.C. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol. 50:1995;1043-1051.
71. Greenberg G.R., Hilfinger J.M. Regulation of synthesis of ribonucleotide reductase and relationship to DNA replication in various systems. Prog Nucleic Acid Res Mol Biol. 53:1996;345-395.
72. Greenberg M., Shum D.E., Wee T.E. Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. Biochem J. 164:1977;379-387.
73. Hapke D.M., Stegmann A.P., Mitchell B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56:1996;2343-2347.
74. Hatzis P., Al-Madhoon A.S., Jullig M., Petrakis T.G., Eriksson S., Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem. 273:1998;30239-30243.
75. He Q., Skog S., Wang N., Eriksson S., Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol. 70:1996;117-124.
76. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
77. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:1990;567-572.
78. Hentosh P., Tibudan M. In vitro transcription of DNA containing 2-chloro-2′deoxyadenosine monophosphate. Mol Pharmacol. 48:1995;897-904.
79. Hentosh P., Tibudan M. 2-Chloro-2′-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol. 51:1997;613-619.
80. Hershfield M.S., Fetter J.E., Small W.C., Bagnara A.S., Williams S.R., Ullman B., Martin D.W., Wasson D.B., Carson D.A. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem. 257:1982;6380-6386.
81. Herzfeld A., Raper S.M. Uridine kinase activities in developing, adult and neoplastic rat tissues. Biochem J. 182:1979;771-778.
82. Honkoop P., Scholte H.R., de Man R.A., Schalm S.W. Mitochondrial injury. Lessons from the fialuridine trial. Drug Safety. 17:1997;1-7.
83. Huang P., Sandoval A., Van Den Neste E., Keating M.J., Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 14:2000;1405-1413.
84. Hubscher U., Nasheuer H.P., Syvaoja J.E. Eukaryotic DNA polymerases, a growing family. Trends Biochem Sci. 25:2000;143-147.
85. Hurley M.C., Lin B., Fox I.H. Regulation of deoxyadenosine and nucleoside analog phosphorylation by human placental adenosine kinase. J Biol Chem. 260:1985;15675-15681.
86. 32P]dTTP of the enzyme from spleen, liver, heart and brain. Eur J Biochem. 206:1992;485-490.
87. Jarvis M.F., Yu H., Kohlhaas K., Alexander K., Lee C.H., Jiang M., Bhagwat S.S., Williams M., Kowaluk E.A. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6- morpholinopyridin-3-yl)pyrido. J Pharmacol Exp Ther. 295:2000;1156-1164.
88. Johansson N.G., Eriksson S. Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim Pol. 43:1996;143-160.
89. Johansson M., Karlsson A. Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase. Biochem Pharmacol. 50:1995;163-168.
90. Johansson M., Karlsson A. Cloning and expression of human deoxyguanosine kinase cDNA. Proc Natl Acad Sci USA. 93:1996;7258-7262.
91. Johansson M., Karlsson A. Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2. J Biol Chem. 272:1997;8454-8458.
92. Johansson M., Bajalica-Lagercrantz S., Lagercrantz J., Karlsson A. Localization of the human deoxyguanosine kinase gene (DGUOK) to chromosome 2p13. Genomics. 38:1996;450-451.
93. Johansson M., Brismar S., Karlsson A. Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA. 94:1997;11941-11945.
94. Johansson M., Van Rompay A.R., Degrève B., Balzarini J., Karlsson A. Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster. J Biol Chem. 274:1999;23814-23819.
95. Johansson K., Ramaswwamy S., Ljungcrantz C., Knecht W., Piskur J., Munch-Petersen B., Eriksson S., Eklund H. Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nat Struct Biol. 8:2001;616-620.
96. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 276:2001;40847-40857.
97. Johnson A.J., Mone A.P., Abhyankar V., Byrd J.C. Advances in the therapy of chronic lymphocytic leukemia. Curr Opin Hematol. 10:2003;297-305.
98. Jüllig M., Eriksson S. Mitochondrial and submitochondrial localization of human deoxyguanosine kinase. Eur J Biochem. 267:2000;5466-5472.
99. Jüllig M., Eriksson S. Apoptosis induces efflux of the mitochondrial matrix enzyme deoxyguanosine kinase. J Biol Chem. 276:2001;24000-24004.
100. Kantarjian H.M., Gandhi V., Cortes J., Verstovsek S., Du M., Garcia-Manero G., Giles F., Faderl S., O'Brien S., Jeha S., Davis J., Shaked Z., Craig A., Keating M., Plunkett W., Freireich E.J. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003, June 5;. (Epub ahead of print).
101. Keating M.J. Chronic lymphocytic leukemia. Semin Oncol. 26:1999;107-114.
102. Kim E.C., Lau J.S., Rawlings S., Lee A.S. Positive and negative regulation of the human thymidine kinase promoter mediated by CCAAT binding transcription factors NF-Y/CBF, dbpA, and CDP/cut. Cell Growth Differ. 8:1997;1329-1338.
103. Kit S., Leung W.C. Submitochondrial localization and characteristics of thymidine kinase molecular forms in parental and kinase-deficient HeLa cells. Biochem Genet. 11:1974;231-247.
104. Klobutcher L.A., Nicols E.A., Kucherlapati R.S., Ruddle F.H. Assignment of the gene for human adenosine kinase to chromosome 10 using a somatic cell hybrid clone panel. Birth Defects Orig Artic Ser. 12:1976;171-174.
105. Knecht W., Petersen G.E., Munch-Petersen B., Piskur J. Deoxyribonucleoside kinases belonging to the thymidine kinase 2 (TK2)-like group vary significantly in substrate specificity, kinetics and feedback regulation. J Mol Biol. 315:2002;529-540.
106. Koizumi K., Shimamoto Y., Azuma A., Wataya Y., Matsuda A., Sasaki T., Fukushima M. Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. Int J Mol Med. 8:2001;273-278.
107. Kornberg A., Baker T.A. DNA replication. Kornberg A., Baker T.A. DNA replication. 2nd ed. 1992;1-931 W.H. Freeman and Company, New York.
108. Kowaluk E.A., Kohlhaas K.L., Bannon A., Gunther K., Lynch J.J., Jarvis M.F. Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Pharmacol Biochem Behav. 63:1999;83-91.
109. Krystal G., Scholefield P.G. The partial purification and properties of uridine kinase from Ehrlich ascites tumor cells. Can J Biochem. 51:1973;379-389.
110. Krystal G., Webb T.E. Multiple forms of uridine kinase in normal and neoplastic rat liver. Biochem J. 124:1971;943-947.
111. Kufe D., Spriggs D., Egan E.M., Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 64:1984;54-58.
112. Kunkel T.A., Bebenek K. DNA replication fidelity. Annu Rev Biochem. 69:2000;497-529.
113. Kuo W.L., Hirschhorn R., Huie M.L., Hirschhorn K. Localization and ordering of acid α-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization. Hum Genet. 97:1996;404-406.
114. Lacombe M.-L., Milon L., Munier A., Mehus J.G., Lambeth D.O. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembranes. 32:2000;247-258.
115. Ladner R.D. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci. 2:2001;361-370.
116. Lavie A., Schlichting I., Vetter I.R., Konrad M., Reinstein J., Goody R.S. The bottleneck in AZT activation. Nat Med. 3:1997;922-924.
117. Lee L.S., Cheng Y.C. Human deoxythymidine kinase: I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. J Biol Chem. 251:1976;2600-2604.
118. Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat Med. 1:1995;417-422.
119. Lewis W., Levine E.S., Griniuviene B., Tankersley K.O., Colacino J.M., Sommadossi J.P., Watanabe K.A., Perrino F.W. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA. 93:1996;3592-3597.
120. Lindsay R.H., Yu M.W. Inhibitory effect of 2-thiouracil and 2-thiouracil metabolism on enzymes involved in the pyrimidine nucleotide biosynthesis. Biochem Pharmacol. 23:1974;2273-2281.
121. Loeb L.A., Mullins J.I. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retrovir. 16:2000;1-3.
122. Loeb L.A., Essigmann J.M., Kazazi F., Zhang J., Rose K.D., Mullins J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA. 96:1999;1492-1497.
123. Lotfi K., Månsson E., Spasokoukotskaja T., Pettersson B., Liliemark J., Peterson C., Eriksson S., Albertioni F. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res. 5:1999;2438-2444.
124. Maj M.C., Singh B., Gupta R.S. Structure-activity studies on mammalian adenosine kinase. Biochem Biophys Res Commun. 275:2000;386-393.
125. Mancuso M., Salviati L., Sacconi S., Otaegui D., Camano P., Marina A., Bacman S., Moraes C.T., Carlo J.R., Garcia M., Garcia-Alvarez M., Monzon L., Naini A.B., Hirano M., Bonilla E., Taratuto A.L., DiMauro S., Vu T.H. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 59:2002;1197-1202.
126. Mandel H., Szargel R., Labay V., Elpeleg O., Saada A., Shalata A., Anbinder Y., Berkowitz D., Hartman C., Barak M., Eriksson S., Cohen N. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondria DNA. Nat Genet. 29:2001;337-341.
127. Manfredi J.P., Holmes E.W. Purine salvage pathways in myocardium. Annu Rev Physiol. 47:1985;691-705.
128. Månsson E., Stridh H., Albertioni F. Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-β-D-arabinofuranosylguanosine. Biochem Biophys Res Commun. 298:2002;338-344.
129. Månsson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., Eriksson S., Albertioni F. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 65:2003;237-247.
130. Mansuri M.M., Starrett J.E. Jr., Ghazzouli I., Hitchcock M.J., Sterzycki R.Z., Brankovan V., Lin T.S., August E.M., Prusoff W.H., Sommadossi J.P., Martin J.C. 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem. 32:1989;461-466.
131. Mascia L., Ipata P.L. Activation pathways of 5-fluorouracil in rat organs and in PC12 cells. Biochem Pharmacol. 62:2001;213-218.
132. Mathews I.I., Erion M.D., Ealick S.E. Structure of human adenosine kinase at 1.5 Å resolution. Biochemistry. 37:1998;15607-15620.
133. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., Di Bisceglie A.M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C., Pruett T., Stotka J.L., Straus S.E., Hoofnagle J.H. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 333:1995;1099-1105.
134. McNally T., Helfrich R.J., Cowart M., Dorwin S.A., Meuth J.L., Idler K.B., Klute K.A., Sdimmer R.L., Kowaluk E.A., Halbert D.N. Cloning and expression of the adenosine kinase gene from rat and human tissues. Biochem Biophys Res Commun. 231:1997;645-650.
135. Miller R.L., Adamczyk D.L., Miller W.H., Koszalka G.W., Rideout J.L., Beacham L.M., Chao E.Y., Haggerty J.J., Krenitsky T.A., Elion G.B. Adenosine kinase from rabbit liver: II. Substrate and inhibitor specificity. J Biol Chem. 254:1979;2346-2352.
136. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA. 83:1986;1911-1915.
137. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Safety. 23:2000;467-781.
138. Munch-Petersen B., Cloos L., Tyrsted G., Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 266:1991;9032-9038.
139. Munch-Petersen B., Cloos L., Jensen H.K., Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul. 35:1995;69-89.
140. Nie Q.H., Luo X.D., Hui W.L. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. World J Gastroenterol. 9:2003;1139-1143.
141. Noble S., Goa K.L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 54:1997;447-472.
142. Ono K., Nakane H., Herdewijn P., Balzarini J., De Clercq E. Differential inhibitory effects of several pyrimidine 2′,3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol Pharmacol. 35:1989;578-583.
143. Orengo A. Regulation of enzyme activity by metabolites: 1. Uridine cytidine kinase of Novikoff ascites rat tumor. J Biol Chem. 244:1969;2204-2209.
144. Owens J.K., Shewach D.S., Ullman B., Mitchell B.S. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 52:1992;2389-2393.
145. Ozaki K., Kuroki T., Hayashi S., Nakamura Y. Isolation of three testis-specific genes (TSA303/TSA806/TSA903) by differential mRNA display method. Genomics. 36:1996;316-319.
146. Palella T.D., Andres C.M., Fox I.H. Human placental adenosine kinase. Kinetic mechanism and inhibition. J Biol Chem. 255:1980;5264-5269.
147. Pasternak C.A., Fischer G.A., Handschumacher R.E. Alterations in pyrimidine metabolism in L5178Y leukemia cells resistant to 6-azauridine. Cancer Res. 21:1961;110-117.
148. Payne S.L., Elder J.H. The role of retroviral dUTPases in replication and virulence. Curr Protein Pept Sci. 2:2001;381-388.
149. Payne R.C., Traut T.W. Regulation of uridine kinase quaternary structure. Dissociation by the inhibitor CTP. J Biol Chem. 257:1982;12485-12488.
150. Petty E.M., Miller D.E., Grant A.L., Collins E.E., Glover T.W., Law D.J. FISH localization of the soluble thymidine kinase gene (TK1) to human 17q25, a region of chromosomal loss in sporadic breast tumors. Cytogenet Cell Genet. 72:1996;319-321.
151. Plunkett W., Gandhi V. Pharmacology of purine nucleoside analogues (Review). Hematol Cell Ther. 38(Suppl 2):1996;S67-S74.
152. Plunkett W., Saunders P.P. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 49:1991;239-268.
153. Plunkett W., Gandhi V., Huang P., Robertson L.E., Yang L.Y., Gregoire V., Estey E., Keating M.J. Fludarabine: pharmacokinetics, mechanism of action, and rationales for combination therapies. Semin Oncol. 20:1993;2-12.
154. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 6(Suppl 6):1995;7-13.
155. Rai K.R., Peterson B.L., Applebaum F.R., Kolitz J., Elias L., Shepherd L., Hines J., Threatte G.A., Larson R.A., Cheson B.D., Schiffer C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 343:2000;1750-1757.
156. Rampazzo C., Gallinaro L., Milanesi E., Frigimelica E., Reichard P., Bianchi V. A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease. Proc Natl Acad Sci USA. 97:2000;8239-8244.
157. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem. 57:1988;349-374.
158. Reichard P., Sköld O. Formation of uridine phosphates from uracil in extracts of Ehrlich ascites tumor. Acta Chem Scand. 11:1957;17-23.
159. Reichard P., Sköld O. Enzymes of uracil metabolism in the Ehrlich ascites tumour and mammalian liver. Biochim Biophys Acta. 28:1958;376-385.
160. Richel D.J., Colly L.P., Arentsen-Honders M.W., Starrenburg C.W., Willemze R. Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle. Leuk Res. 14:1990;363-369.
161. Rodriguez C.O. Jr., Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 59:1999;4937-4943.
162. Rodriguez C.O. Jr., Mitchell B.S., Ayres M., Eriksson S., Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 62:2002;3100-3105.
163. Ropp P.A., Traut T.W. Cloning and expression of a cDNA encoding uridine kinase from mouse brain. Arch Biochem Biophys. 336:1996;105-112.
164. Ropp P.A., Traut T.W. Uridine kinase: altered enzyme with decreased affinities for uridine and CTP. Arch Biochem Biophys. 359:1998;63-68.
165. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 46:1993;762-766.
166. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., Vermorken J.B., Pinedo H.M., Peters G.J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54:1994;4138-4143.
167. Saada A., Shaag A., Mandel H., Nevo Y., Eriksson S., Elpeleg O. Mutant
168. Sabini E., Ort S., Monnerjahn C., Konrad M., Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 10:2003;513-519.
169. Sales S.D., Hoggard P.G., Sunderland D., Khoo S., Hart C.A., Back D.J. Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol. 177:2001;54-58.
170. Salviati L., Sacconi S., Mancuso M., Otaegui D., Camano P., Marina A., Rabinowitz S., Shiffman R., Thompson K., Wilson C.M., Feigenbaum A., Naini A.B., Hirano M., Bonilla E., DiMauro S., Vu T.H. Mitochondrial DNA depletion and dGK gene mutations. Ann Neurol. 52:2002;311-317.
171. Sandoval A., Consoli U., Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 2:1996;1731-1741.
172. Sarup J.C., Friland A. Identification of purine deoxyribonucleoside kinases from human leukemia cells: substrate activation by purine and pyrimidine deoxyribonucleosides. Biochemistry. 26:1987;590-597.
173. Scharenberg J.G., Spaapen L.J., Rijkers G.T., Wadman S.K., Staal G.E., Zegers B.J. Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol. 195:1986;191-199.
174. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.B., Liotta D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine. Antimicrob Agents Chemother. 36:1992;2423-2431.
175. Schumacher M.A., Scott D.M., Mathews I.I., Ealick S.E., Roos D.S., Ullman B., Brennan R.G. Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding. J Mol Biol. 298:2000;875-893.
176. Shen F., Look K.Y., Yeh Y.A., Weber G. Increased uridine kinase (ATP: uridine 5′-phosphotransferase (EC 2.7.1.48)) activity in human and rat tumors. Cancer Biochem Biophys. 16:1998;1-15.
177. Sherley J.L., Kelly T.J. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem. 263:1988;375-382.
178. Shewach D.S., Reynolds K.K., Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol. 42:1992;518-524.
179. Siegmund B., Rieder F., Albrich S., Wolf K., Bidlingmaier C., Firestein G.S., Boyle D., Lehr H.A., Loher F., Hartmann G., Endres S., Eigler A. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 296:2001;99-105.
180. Sjoberg A.H., Wang L., Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol Pharmacol. 53:1998;270-273.
181. Sköld O. Uridine kinase from Ehrlich ascites tumor: purification and properties. J Biol Chem. 235:1960;3273-3279.
182. Sköld O. Enzymes of uracil metabolism in tissues with different growth characteristics. Biochim Biophys Acta. 44:1960;1-12.
183. Smith D.A., Visser D.W. Studies on 5-hydroxyuridine. J Biol Chem. 240:1965;446-453.
184. Solary E., Bettaieb A., Dubrez-Daloz L., Corcos L. Mitochondria as a target for inducing death of malignant hematopoietic cells. Leuk Lymphoma. 44:2003;563-574.
185. Soudeyns H., Yao X.I., Gao Q., Belleau B., Kraus J.L., Nguyen-Ba N., Spira B., Wainberg M.A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother. 35:1991;1386-1390.
186. Spasokukotskaja T., Arnér E.S.J., Brosjö O., Gunvén P., Juliussion G., Liliemark J., Eriksson S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer. 31A:1995;202-208.
187. Spychala J., Datta N.S., Takabayashi K., Datta M., Fox I.H., Gribbin T., Mitchell B.S. Cloning of human adenosine kinase cDNA. Sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci USA. 93:1996;1232-1237.
188. Starnes M.C., Cheng Y.C. Cellular metabolism of 2′,3′- dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem. 262:1987;988-991.
189. Stegmann A.P., Honders M.W., Bolk M.W., Wessels J., Willemze R., Landegent J.E. Assignment of the human deoxycytidine kinase (DCK) gene to chromosome 4 band q13.3-q21.1. Genomics. 17:1993;528-529.
190. Studebaker A.W., Balendiran G.K., Williams M.V. The herpesvirus encoded dUTPase as a potential chemotherapeutic target. Curr Protein Pept Sci. 2:2001;371-379.
191. Szebeni J., Patel S.S., Hung K., Wahl L.M., Weinstein J.N. Effects of thymidine and uridine on the phosphorylation of 3′-azido-3′- deoxythymidine (zidovudine) in human mononuclear cells. Antimicrob Agents Chemother. 35:1991;198-200.
192. Taanman J.W. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta. 1410:1999;103-123.
193. Takatori S., Kanda H., Takenaka K., Wataya Y., Matsuda A., Fukushima M., Shimamoto Y., Tanaka M., Sasaki T. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-β-D-ribo- pentofuranosyl)cytosine and 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol. 44:1999;97-104.
194. Tan X., Chu C.K., Boudinot F.D. Development and optimalization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure-activity relationship and pharmacokinetics. Adv Drug Deliv Rev. 39:1999;117-151.
195. Timsit Y. DNA structure and polymerase fidelity. J Mol Biol. 293:1999;835-853.
196. Törnevik Y., Ullman B., Balzarini J., Wahren B., Eriksson S. Cytotoxicity of 3′-azido-3′deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol. 49:1995;829-837.
197. Traut T.W., Jones M.E. Uracil metabolism-UMP synthesis from orotic acid or uridine and conversion of uracil to β-alanine enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol. 53:1996;1-78.
198. Tseng W.C., Derse D., Cheng Y.C., Brockman R.W., Bennett L.L. Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 21:1982;474-477.
199. Turk B., Awad R., Usova E., Björk I., Eriksson S. A pre-steady-state kinetic analysis of substrate binding to human recombinant deoxycytidine kinase: a model for nucleoside kinase action. Biochemistry. 38:1999;8555-8561.
200. Ugarkar B.G., Castellino A.J., DaRe J.M., Kopcho J.J., Wiesner J.B., Schanzer J.M., Erion M.D. Adenosine kinase inhibitors: 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. J Med Chem. 43:2000;2894-2905.
201. Ullman B., Gudas L.J., Cohen A., Martin D.W. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell. 14:1978;365-375.
202. Ullman B., Coons T., Rockwell S., McCartan K. Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem. 263:1988;12391-12396.
203. Usova E.V., Eriksson S. Identification of residues involved in the substrate specificity of human and murine dCK. Biochem Pharmacol. 64:2002;1559-1567.
204. Van Rompay, A.R. (2001). Identification and characterization of nucleoside and nucleotide kinases: pharmacological activation of anti-cancer and anti-viral nucleoside analogs. PhD thesis. Stockholm: Karolinska Institute.
205. Van Rompay A.R., Johansson M., Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase; molecular characterization of the human enzyme. Mol Pharmacol. 56:1999;562-569.
206. Van Rompay A.R., Johansson M., Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther. 87:2000;189-198.
207. Van Rompay A.R., Norda A., Lindén K., Johansson M., Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 59:2001;1181-1186.
208. Verhoef V., Sarup J., Friland A. Identification of the mechanism of activation of 9-β-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. Cancer Res. 41:1981;4478-4483.
209. Verschuur A.C., Van Gennip A.H., Leen R., Muller E.J., Elzinga L., Voute P.A., Van Kuilenburg A.B. Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. Eur J Cancer. 36:2000;627-635.
210. Vesely J., Cihak A. Resistance of mammalian tumor cells toward pyrimidine analogues. A review. Oncology. 38:1973;204-226.
211. Vesely J., Cihak A. Uridine kinase in embryonic rat liver: modulation of enzyme activity by 5-azacytidine. Biochem J. 133:1973;609-613.
212. Wang J., Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5- iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 40:1996;1555-1557.
213. Wang L., Eriksson S. Cloning and characterization of full-length mouse thymidine kinase 2: the N terminal sequence directs import of the precursor protein into mitochondria. Biochem J. 351:2000;469-476.
214. Wang L., Karlsson A., Arnér E.S., Eriksson S.J. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem. 268:1993;22847-22852.
215. Wang L., Munch-Petersen B., Herrstrom Sjoberg A., Hellman U., Bergman T., Jornvall H., Eriksson S. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. 443:1999;170-174.
216. Waud W.R., Schmid S.M., Montgomery J.A., Secrist J.A. III Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-D-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids. 19:2000;447-460.
217. Weichsel M.E. Jr., Hoogenraad N.J., Levine R.L., Kretchmer N. Pyrimidine biosynthesis during development of rat cerebellum. Pediatr Res. 6:1972;682-686.
218. Wettin K., Johansson M., Zheng X., Zhu C., Karlsson A. Cloning of mouse mitochondrial thymidine kinase 2 cDNA. FEBS Lett. 460:1999;103-106.
219. White J.C., Hines L.H. Role of uridine triphosphate in the phosphorylation of 1-β-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. Cancer Res. 47:1987;1820-1824.
220. Wiley J.S., Jones S.P., Sawyer W.H., Paterson A.R. Cytosine arabinoside influx and nucleoside transport sites in leukemia. J Clin Invest. 69:1982;479-489.
221. Willis R.C., Carson D.A., Seegmiller J.E. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA. 75:1978;3042-3044.
222. Wright J.A., Chan A.K., Choy B.K., Hurta R.A., McClarty G.A., Tagger A.Y. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol. 68:1990;1364-1371.
223. Xu Y.Z., Huang P., Plunkett W. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem. 270:1995;631-637.
224. Yamada Y., Goto H., Ogasawara N. Adenosine kinase from human liver. Biochim Biophys Acta. 660:1981;36-43.
225. Zannis-Hadjppoulus M., Price G.B. Eukaryotic DNA replication. J Cell Biochem Suppl. 32-33:1999;1-14.
226. Zhu, C. (2000). Deoxyribonucleoside kinases in nuclear and mitochondrial DNA precursor synthesis: phosphorylation of anti-cancer nucleoside analogs in different subcellular compartments. PhD thesis. Stockholm: Karolinska Institute.
227. Zhu C., Johansson M., Permert J., Karlsson A. Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase. Biochem Pharmacol. 56:1998;1035-1040.
228. Zhu C., Johansson M., Permert J., Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J Biol Chem. 273:1998;14707-14711.
229. Zhu C., Johansson M., Karlsson A. Differential incorporation of 1-β-D-arabinofuranosylcytosine and 9-β-D-arabinofuranosylguanine into nuclear and mitochondrial DNA. FEBS Lett. 474:2000;129-132.